Swartz Robin
SEC CIK 1909636 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| VYGR | Voyager Therapeutics, Inc. | COO, CBO | 199.7K | — | $451.4K | 20 | 2022-03-21 | 2026-02-24 |
Most active insiders at VYGR, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Sandrock Alfred | Pres, CEO, Dir | — | $184.4K |
| 2 | Swartz Robin | COO, CBO | — | $55.3K |
| 3 | Jorgensen Nathan D. | CFO | — | $54.2K |
| 4 | Carter Todd Alfred | CSO | — | $40.6K |
| 5 | Shiferman Gregory L. | SVP, GC | — | — |
| 6 | Ferguson Toby | Chief Medical Off | — | — |
Transactions 20
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-26 | 2026-02-24 | VYGR | Voyager Therapeutics, Inc. | Swartz Robin | COO, CBO | S - Sale | $3.77 | -6,458 | 199.7K | -3% | -$24.3K | |
| 2026-02-20 | 2026-02-18 | VYGR | Voyager Therapeutics, Inc. | Swartz Robin | COO, CBO | S - Sale | $3.44 | -3,882 | 206.2K | -2% | -$13.4K | |
| 2026-02-11 | 2026-02-10 | VYGR | Voyager Therapeutics, Inc. | Swartz Robin | COO, CBO | S - Sale | $3.85 | -4,569 | 210.1K | -2% | -$17.6K | |
| D | 2026-02-10 | 2026-02-06 | VYGR | Voyager Therapeutics, Inc. | Swartz Robin | COO, CBO | A - Grant | $0.00 | +45.0K | 214.6K | +27% | $0 |
| D | 2025-02-24 | 2025-02-21 | VYGR | Voyager Therapeutics, Inc. | Swartz Robin | COO, CBO | A - Grant | $0.00 | +71.2K | 169.6K | +72% | $0 |
| D | 2025-02-24 | 2025-02-20 | VYGR | Voyager Therapeutics, Inc. | Swartz Robin | COO, CBO | S - Sale | $4.25 | -3,894 | 98.4K | -4% | -$16.5K |
| 2025-02-12 | 2025-02-11 | VYGR | Voyager Therapeutics, Inc. | Swartz Robin | COO, CBO | S - Sale | $4.45 | -6,950 | 102.3K | -6% | -$30.9K | |
| 2025-01-15 | 2025-01-14 | VYGR | Voyager Therapeutics, Inc. | Swartz Robin | COO, CBO | S - Sale | $5.09 | -3,087 | 109.2K | -3% | -$15.7K | |
| 2024-12-26 | 2024-12-23 | VYGR | Voyager Therapeutics, Inc. | Swartz Robin | COO, CBO | S - Sale | $5.65 | -6,500 | 112.3K | -5% | -$36.7K | |
| 2024-04-03 | 2024-04-02 | VYGR | Voyager Therapeutics, Inc. | Swartz Robin | COO | S - Sale | $9.88 | -1,357 | 117.0K | -1% | -$13.4K | |
| 2024-02-22 | 2024-02-21 | VYGR | Voyager Therapeutics, Inc. | Swartz Robin | COO | S - Sale | $7.45 | -3,966 | 118.4K | -3% | -$29.5K | |
| D | 2024-02-16 | 2024-02-09 | VYGR | Voyager Therapeutics, Inc. | Swartz Robin | COO | A - Grant | $0.00 | +50.0K | 122.3K | +69% | $0 |
| 2024-01-19 | 2024-01-17 | VYGR | Voyager Therapeutics, Inc. | Swartz Robin | COO | S - Sale | $7.15 | -2,543 | 72.3K | -3% | -$18.2K | |
| 2023-04-05 | 2023-04-03 | VYGR | Voyager Therapeutics, Inc. | Swartz Robin | COO | S - Sale | $7.83 | -1,259 | 71.6K | -2% | -$9,858 | |
| 2023-03-22 | 2023-03-20 | VYGR | Voyager Therapeutics, Inc. | Swartz Robin | COO | S - Sale | $7.76 | -3,654 | 72.9K | -5% | -$28.4K | |
| 2023-03-17 | 2023-03-15 | VYGR | Voyager Therapeutics, Inc. | Swartz Robin | COO | S - Sale | $8.20 | -15.4K | 76.5K | -17% | -$126.1K | |
| D | 2023-02-22 | 2023-02-17 | VYGR | Voyager Therapeutics, Inc. | Swartz Robin | COO | A - Grant | $0.00 | +40.0K | 91.9K | +77% | $0 |
| M | 2023-01-19 | 2023-01-17 | VYGR | Voyager Therapeutics, Inc. | Swartz Robin | COO | S - Sale | $9.85 | -2,188 | 51.9K | -4% | -$21.5K |
| 2022-04-06 | 2022-04-04 | VYGR | Voyager Therapeutics, Inc. | Swartz Robin | COO | S - Sale | $8.25 | -1,527 | 52.1K | -3% | -$12.6K | |
| M | 2022-03-23 | 2022-03-21 | VYGR | Voyager Therapeutics, Inc. | Swartz Robin | COO | S - Sale | $8.29 | -4,413 | 53.6K | -8% | -$36.6K |
Purchase Sale Sale after option exercise All abbreviations